ARQT - Arcutis completes enrollment in late-stage ARQ-151 study for plaque psoriasis September, 16 2020 09:43 AM Arcutis Biotherapeutics Inc. Arcutis Biotherapeutics (ARQT -0.4%) has completed enrollment in DERMIS-1 and DERMIS-2, the Company’s pivotal Phase 3 clinical trials evaluating ARQ-151 (topical roflumilast cream) as a potential topical treatment for plaque psoriasis.More news on: Arcutis Biotherapeutics, Inc., Healthcare stocks news, Read more ...